Population health is not a “nice to have” – it’s the only way the NHS survives

Harry Thirkettle, director of health & innovation, Aire Logic

For years, population health management (PHM) has been talked about as an ambition: something progressive systems invest in when they have the time, money or headspace.

That framing is no longer tenable. PHM is not a digital add-on, a policy aspiration or an innovation programme. It is the only credible route to a sustainable health system.

The uncomfortable truth is that the NHS is attempting to meet 21st-century levels of chronic disease with a model of care designed for acute, episodic illness.

Diabetes, cardiovascular disease, COPD, frailty and multi-morbidity now dominate demand, cost and workforce pressure – yet we still largely intervene late, once conditions have deteriorated, patients are at crisis point, and options are limited.

That is not a failure of effort or compassion; it is a failure to evolve our healthcare system to meet the new challenges posed by chronic conditions.

Globally, chronic disease is forecast to cost more than $47 trillion over the next decade.

In the UK, long-term conditions already account for the majority of NHS spend and activity.

If current trends continue, no amount of efficiency savings or service reconfiguration will close the gap.

Prevention and early intervention are not “nice to have” extras, they are the only levers that meaningfully change the trajectory.

This is where population health management matters.

At its best, PHM allows us to identify risk earlier, understand need across whole populations, and intervene before people develop long term conditions, or slow progress from manageable conditions into lifelong dependency on services.

Done properly, it shifts the system from reacting to disease to actively preventing it.

We are starting to see what this looks like in practice.

Linked datasets that bring together primary care, community, mental health and acute data make it possible to see how people with long-term conditions move through the system over time.

Risk stratification tools embedded into everyday clinical systems create a shared language for need, enabling clinicians to prioritise proactively rather than relying on blunt organisational processes.

In chronic disease management, this can be transformative. Instead of reviewing patients with diabetes or hypertension on an arbitrary annual cycle, services can focus effort where deterioration risk is highest.

Instead of waiting for complications to present, care teams can intervene earlier with lifestyle support, medication optimisation or community-based interventions.

Over a lifetime, the clinical and economic impact of preventing progression from pre-diabetes to Type 2 diabetes, or from mild COPD to advanced disease, is enormous.

And yet, despite this promise, PHM remains fragile and unevenly adopted.

One reason is that our funding and accountability models are fundamentally misaligned with prevention.

Boards and finance teams are under intense pressure to deliver in-year savings.

Preventative interventions, by definition, create value over years or decades. When success is measured in months, prevention will always struggle to compete.

This is not a theoretical problem.

Early-stage innovations that could delay or prevent chronic disease progression often fail to secure funding because their benefits do not land neatly within a single financial year or organisational boundary.

The result is a system that repeatedly pays for the downstream consequences of chronic illness, while starving the upstream interventions that would reduce demand in the first place.

There is also a tendency to treat PHM as a series of dashboards rather than a change in how care is delivered.

Data alone does nothing. The real impact comes when insight is embedded at the point of care, influencing clinical decision-making and behaviour.

If risk stratification sits in a report rather than in the clinical workflow, it will not change outcomes.

Crucially, prevention at scale requires robust digital foundations.

Fragmented systems, inconsistent data standards and siloed architectures make it impossible to track long-term conditions across pathways and over time.

Open standards and interoperability are not technical preferences; they are prerequisites for prevention.

Without them, we cannot reliably identify risk, leverage the potential benefits of AI, evaluate impact or learn what works.

None of this is easy.

Building PHM capability takes time, trust and sustained investment. It requires leaders to step back from firefighting and think differently about value.

It also requires honesty about the fact that the current trajectory is unsustainable.

Continuing to optimise a reactive system without reducing demand will not solve a problem that is fundamentally preventative in nature.

If PHM is to succeed, it must be treated as core national infrastructure, not discretionary innovation.

That means aligning incentives with long-term outcomes, mandating interoperable data standards, and creating space for systems to invest in prevention without being penalised for failing to deliver immediate cash savings.

We should also be clear about what we still do not know.

We need stronger UK-specific evidence on the long-term return on investment of PHM in chronic disease prevention.

We need better modelling of when preventative interventions break even financially, and how savings accrue across the system rather than within single organisations.

We need clearer national measures of success that go beyond pilot outcomes and short-term utilisation metrics.

But uncertainty is not an excuse for inaction. The direction of travel is clear.

A health system dominated by chronic disease cannot be sustained by reactive care alone.

Prevention is not a “nice to have”.

Population health management is how we make it real – and without it, the future of the NHS becomes increasingly hard to imagine.